Plempel M
Postgrad Med J. 1979 Sep;55(647):662-6. doi: 10.1136/pgmj.55.647.662.
According to data on the imidazole antimycotics at present on the market, none of these products satisfactorily fills the gaps which exist in the treatment for mycoses of internal organs, although they have brought considerable progress in the topical treatment of mycoses. On the basis of their very broad spectrum and high intensity of activity under suitable test conditions, and the comparatively tolerable amount of side effects in man, the present imidazole antimycotics are considered to be an encouraging start for future development of derivatives which will lead to products with considerably better pharmacokinetic, and therefore better therapeutic, properties.
根据目前市场上咪唑类抗真菌药的数据,尽管这些产品在真菌病的局部治疗方面取得了显著进展,但没有一种产品能令人满意地填补内脏真菌病治疗中存在的空白。基于其非常广泛的谱和在合适测试条件下的高活性强度,以及在人体中相对可耐受的副作用量,目前的咪唑类抗真菌药被认为是未来衍生物开发的一个令人鼓舞的开端,这些衍生物将产生具有更好药代动力学,从而具有更好治疗特性的产品。